Introduction
============

Venous thromboembolism (VTE) is one of the leading causes of maternal morbidity and mortality in pregnancy.[@B1] The incidence of VTE is estimated to be 0.76 to 1.72 per 1,000 pregnancies, which is four times greater than the risk in the non-pregnant population.[@B2] Pregnancy itself induces a prothrombotic state with an increase in coagulation factors, a decrease in natural anticoagulants such as the coagulation inhibitor protein S, and impairment of fibrinolysis, which is probably mediated by an increase in plasminogen activator inhibitor.[@B3] These procoagulant changes are important for minimizing blood loss during delivery. Pregnancy is also marked by the presence of two other components of Virchow\'s triad, venous stasis and endothelial injury. These homeostatic changes cause an increased risk for VTE.[@B3]

A hypercoagulable state during pregnancy is known to be the most important factor for increasing the risk of VTE. In addition to inherited thrombophilia or the antiphospholipid syndrome, the assisted reproduction technique (ART), cesarean (C)-section, age older than 35 years, obesity, multiple pregnancies, placenta previa, pregnancy-induced hypertension (PIH), and gestational diabetes mellitus (GDM) are also known risk factors.[@B1][@B4]-[@B8] Particularly among pregnancy-related diseases, PIH and GDM are common during pregnancy, with incidences of 6% to 8%, and 2.2% to 8.8%, respectively, and are known as VTE risk factors.[@B9][@B10] However, recent research has questioned the relevance of PIH or diabetes mellitus (DM) to VTE.[@B11][@B12] Therefore, this study was undertaken to identify the risk factors for the development of VTE in pregnancy, and to determine the contributions of PIH and GDM.

Subjects and Methods
====================

Study population
----------------

This was a retrospective study of 27 VTE patients out of 57,009 pregnancies at Cheil General Hospital from January 2002 to December 2008. Case controls were 56,982 patients who did not have VTE during or within four weeks after pregnancy, within the same time period.

Diagnostic criteria and data collection
---------------------------------------

The general characteristics of patients and known risk factors for VTE, including premature rupture of membrane (PROM), GDM, PIH, C-section, and ART were obtained through chart review. The study was approved by the Institutional Review Board of Cheil General Hospital, and authorization for the use of data retrieved from medical records for research purposes was also obtained. Only patients with manifestations of proximal deep vein thrombosis (DVT) and pulmonary embolism (PE) were considered to have VTE and were studied. The diagnosis of DVT was objectively confirmed by an intraluminal filling defect and noncompression viewed by color Doppler ultrasonography. PE was confirmed by observation of an intraluminal filling defect on computed tomography pulmonary angiography.

PIH includes gestational hypertension, preeclampsia/eclampsia, and preeclampsia superimposed on chronic hypertension. To diagnose GDM, a 50 g oral glucose tolerance (OGT) test was conducted at 24-28 weeks of pregnancy. When the glucose level in a 50 g OGT test was greater than 140 mg/dL, a 100 g OGT test was performed. According to the Carpenter-Coustan criteria,[@B13] GDM was diagnosed when patient glucose levels exceeded two or more of the following thresholds: fasting glucose, 95 mg/dL; one hour glucose, 180 mg/dL; two hour, 155 mg/dL; or three hour, 140 mg/dL.

Statistical analysis
--------------------

Statistical Package for the Social Sciences (SPSS) 12.0 for Windows (SPSS, Chicago, IL, USA) was used for statistical analysis. Results were expressed as the mean±SD. Risk factors for VTE were analyzed using a Chi-square test and linear logistic regression models, and are presented as risk ratios with 95% confidence interval (CI). Statistical significance was considered to be p\<0.05.

Results
=======

There were 27 VTE patients identified out of 57,009 deliveries, for a frequency of 0.47 VTE patients/1,000 deliveries, which is similar to the results of other studies. The mean patient age was 31.8±3.5 years (17-53 years) at the time of delivery. In this study, the frequency of PE was 0.035%, higher than the 0.012% for DVT. The rate for C-section delivery was 38.8%, for multiple pregnancies was 2.6%, for GDM was 1.9%, for PIH was 1.3%, for placenta previa was 0.6%, and for PROM was 8.9%. ART was used in 4.3% of patients ([Table 1](#T1){ref-type="table"}).

To identify the risk factors associated with pregnancy-induced VTE, univariate analysis using a Chi-square test was performed. As variables, PIH and GDM, in addition to traditional risk factors for VTE, such as age, C-section, multiple pregnancy, placenta previa, and ART were included. C-section (p=0.000), multiple pregnancy (p=0.000), PIH (p=0.000), placenta previa (p=0.000), and ART (p=0.000) were statistically significant compared to the controls. However, age (p=0.061), PROM (p=0.782), and GDM (p=0.475), which are thought to be risk factors for VTE, were not statistically associated with VTE ([Table 2](#T2){ref-type="table"}). Using logistic regression analysis, the odds ratios of risk factors were calculated. Placenta previa had a 12.6-fold higher risk, and PIH had a 9.8-fold higher risk for the occurrence of VTE. C-section and ART procedures increased the risk for VTE 4.2-fold compared to the controls. Multiple gestations, which showed a close correlation by univariate analysis, demonstrated no significant association (p=0.149) ([Table 3](#T3){ref-type="table"}) ([Fig. 1](#F1){ref-type="fig"}). Age, GDM, and placenta abruptio did not increase the risk for VTE during or after pregnancy.

Discussion
==========

In this study, we found that PIH was closely correlated with pregnancy-induced VTE. Another new finding was that placenta previa contributed to the development of VTE, which has not been seen in other studies. Moreover, we found that there was no association of VTE with patient age or GDM, which are usually assumed to be VTE risk factors in pregnancy.

Because VTE during pregnancy or after delivery may be fatal to both mother and baby, understanding the risk factors and providing early thromboprophylaxis can help prevent VTE development.[@B14] More than 50% of VTE occurs in the first two trimesters, and use of early thromboprophylaxis has been emphasized during pregnancy of patients at high risk for VTE. One of the most important risk factors for VTE in pregnancy is a history of thrombosis.[@B11][@B15]-[@B17] In addition to thrombophilia, many studies have reported that C-section, PIH, multiparity, multiple gestation, GDM, and age (age \>35) are risk factors for VTE in pregnancy.[@B7][@B18][@B19] In a large Swedish study, C-section increased the risk of postpartum thrombosis by 5-fold,[@B7] and this result was confirmed in another study.[@B19]

Preeclampsia is known as a significant risk factor for VTE. Lindqvist et al.[@B7] found no association of preeclampsia with antepartum VTE, but preeclampsia increased the risk of postpartum VTE by 3-fold. However, Ros et al.[@B8] reported that preeclampsia was associated with both antepartum and postpartum VTE. In severe preeclampsia, the risk for VTE was elevated 4.8-fold. In another study determining the association of hypertensive pregnancy with cardiovascular (CV) and thromboembolic events, gestational hypertension, mild preeclampsia, and severe preeclampsia increased the risk for VTE by 2.8-, 2.2-, and 3.3-fold, respectively.[@B20] A number of mechanisms may explain the observed association between VTE and CV disease. Adverse physiological changes developing during preeclampsia, such as endothelial cell dysfunction, hemodynamic abnormalities, and insulin resistance may contribute to VTE occurrence during and after delivery.[@B21][@B22]

In diabetes, high blood glucose promotes vascular inflammation leading to increased risk of a CV event. Regarding study on the association between diabetes and VTE, a population-based case-control study, based on Rochester Epidemiology Project data from 1976 to 2000, showed that DM and diabetes complications are not independent risk factors for incident VTE.[@B12] The theoretical mechanism that leads to the development of VTE, is that the atherosclerotic risk factors of diabetes, infection and hypercoagulability, affect VTE development. Many studies have revealed the association of diabetes with VTE and PE,[@B23][@B24] and results of a recent meta-analysis that diabetes increased the risk for VTE 1.42-fold (95% CI, 1.12-1.77) support the association.[@B25] A register-based case-control study in Norway also showed that GDM increased antenatal VTE by 4.0-fold (95% CI, 2.0-8.9).[@B1] Interestingly, they did not find that GDM predicts postnatal VTE, suggesting that antepartum and postpartum VTE may involve different developmental mechanisms. Therefore, large differences exist between the unadjusted and adjusted odd ratios for all postnatal risk factors (preeclampsia, placenta previa, placenta abruptio, ART, and C-section). In this study, age and multiple pregnancies, which have been thought to be risk factors for VTE in pregnancy, demonstrated no association with postnatal VTE.

Our study reconfirmed the known risk factors of VTE in pregnancy, including the strong relationship between PIH and VTE in pregnancy, and found another new risk factor, placenta previa. Since in this study, age and GDM were not risk factors for VTE in pregnancy, if our results are confirmed, this finding could help reduce unnecessary diagnostic tests and the use of thromboprophylaxis. Even though thromboprophylaxis during pregnancy is relatively safe, bleeding, osteoporosis, thrombocytopenia, skin necrosis, and other adverse effects frequently continue to occur after anticoagulation therapy.[@B26]-[@B28] More research is needed to produce better guidelines for thromboprophylaxis.

Our study has many limitations. Most importantly, this study was performed in one center and had a very small number of patients. Because the frequency of VTE is so low, it is difficult to conduct an association study in a single center; therefore, multicenter registry studies are needed. Another limitation is that our study did not consider the difference between antepartum and postpartum VTE. In our study, we had only five cases of antepartum VTE, and the remaining 22 cases developed in the postpartum period. Therefore, our results are more relevant to postpartum VTE, and more cases are needed to clarify VTE differences occurring before and after delivery, because ante- and postpartum risk patterns are different. Moreover, the diagnosis of DVT during pregnancy is generally hard to make. Since dyspnea, tachypnea, swelling, and discomfort in the legs are common during pregnancy and sometimes go without treatment, the incidence of actual DVT seems to be underestimated. This is why the incidence of DVT in our study was so low, and more aggressive effort should be devoted to the diagnosis of DVT in a larger study.

In conclusion, our study revealed that PIH, but not GDM, was associated with VTE in pregnancy. However, a large-scale, multicenter registry study is still required to determine the relationship between GDM and VTE.
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Baseline characteristics of the study population
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VTE: venous thromboembolism, PIH: pregnancy-induced hypertension, PROM: premature rupture of the membrane, ART: assisted reproduction technology
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Risk factors for VTE in pregnancy (univariate analysis)
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VTE: venous thromboembolism, PIH: pregnancy-induced hypertension, PROM: premature rupture of the membrane, ART: assisted reproduction technology (χ^2^-test)
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Risk factors for venous thromboembolism in pregnancy (multiple regression analysis)
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GDM: gestational diabetes mellitus, PIH: pregnancy-induced hypertension, ART: assisted reproduction technology
